Conference Paper
RDF
pages:
-
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
-
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
-
A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
-
A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
-
A phase 2 trial of high-dose allovectin-7 in patients with advanced metastatic melanoma.
-
A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.
-
A phase 2a study to investigate drug–drug interactions between escalating doses of AT2220 (duvoglustat hydrochloride) and acid alfa-glucosidase in subjects with Pompe disease
-
A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS
-
A Phase 3 Single-Arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Steroid Refractory Acute Gvhd in Pediatric Patients
-
A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
-
A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
-
A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.
-
A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery
-
A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
-
A phase I hyperthermia-induced interleukin-12 gene-therapy trial in a spontaneously arising feline soft tissue sarcoma model
-
A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
-
A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors
-
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
-
A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity
-
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
-
A Phase I study of pegylated-uricase (Puricase (R)) in subjects with gout.
-
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
-
A Phase I Study Of Prm-151 In Patients With Idiopathic Pulmonary Fibrosis
-
A phase i study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
-
A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
-
A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
-
A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.
-
A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors
-
A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.
-
A phase I trial of AP23573, a novel mTOR inhibitor, in patients (Pts) with recurrent malignant glioma.
pages: